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MaBACKGROUND Controversy over blood pressure (BP) treatment targets for individuals with diabetes is in part due to
conflicting perspectives about generalizability of available trial data.
OBJECTIVE The authors sought to estimate how results from the largest clinical trial of intensive BP treatment among
adults with diabetes would generalize to the U.S. population.
METHODS The authors used transportability methods to reweight individual patient data from the ACCORD (Action to
Control Cardiovascular Risk in Diabetes) BP trial (N ¼ 4,507) of intensive (goal systolic BP <120 mm Hg) versus standard
(goal systolic BP <140 mm Hg) treatment to better represent the demographic and clinical risk factors of the U.S.
population of adults with diabetes (data from NHANES [National Health and Nutrition Examination Survey] 2005 to
2014, n ¼ 1,943). The primary outcome was the first occurrence of nonfatal myocardial infarction, nonfatal stroke, or
cardiovascular death. Analysis used weighted Cox proportional hazards regression models with robust standard errors.
RESULTS The ACCORD BP sample had less racial/ethnic diversity and more elevated cardiovascular risk factors than the
NHANES participants. Weighted results significantly favored intensive BP treatment, unlike unweighted results (hazard
ratio for primary outcome in intensive versus standard treatment in weighted analyses: 0.67, 95% confidence interval:
0.49 to 0.91; in unweighted analyses: hazard ratio: 0.88, 95% confidence interval: 0.73 to 1.07). Over 5 years, the
weighted results estimate a number needed to treat of 34, and number needed to harm of 55.
CONCLUSIONS After reweighting to better reflect the U.S. adult population with diabetes, intensive BP therapy was
associated with significantly lower risk for cardiovascular events. However, data were limited among racial/ethnic mi-
norities and those with lower cardiovascular risk. (J Am Coll Cardiol 2018;72:1214–23) © 2018 by the American College of
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AB BR E V I A T I O N S
AND ACRONYM S
ACC = American College of
Cardiology
AHA = American Heart
Association
BP = blood pressure
CI = confidence interval
DM = diabetes mellitus
FPG = fasting plasma glucose
HbA1c = hemoglobin A1c
HR = hazard ratio
MI = myocardial infarction
SBP = systolic blood pressureU ncontrolled blood pressure (BP) remains aleading cause of excess cardiovascularmorbidity and mortality among patients
with diabetes mellitus (DM) (1). Determining the
appropriate BP control target is of major clinical and
public health importance. However, the BP targets
to adopt for this population remain controversial,
with conflicting recommendations from different
guideline-issuing groups. The 2017 update of the
American College of Cardiology (ACC)/American
Heart Association (AHA) BP treatment guidelines (2)
recommend universal intensive BP treatment for
adults with DM (target BP <130/80 mm Hg). The
2018 Standards of Care in Diabetes from the American
Diabetes Association, however, recommend a target
of <140/90 mm Hg for most patients (3). Similarly,
the American College of Physicians and the American
Academy of Family Physicians have not endorsed the
ACC/AHA hypertension guidelines for individuals
with DM (4). The differences among guidelines leave
individual practitioners and patients with a dilemma
when deciding on a target BP. 
SEE PAGE 1224The differences among current guidelines largely
result from different interpretations of how to
generalize 2 large randomized trials. The SPRINT trial
(Systolic Blood Pressure Intervention Trial) (5)
enrolled high-risk individuals without DM to
intensive versus standard BP control (systolic
target <120 mm Hg vs. <140 mm Hg) and found a 27%
reduction in mortality for intensive BP treatment. Yet
the largest randomized clinical trial of intensive BP
treatment among people with DM, the ACCORD BP
(Action to Control Cardiovascular Risk in Diabetes—
Blood Pressure) trial did not find significant benefit of
intensive BP treatment for its primary outcome (a
composite of nonfatal myocardial infarction (MI),
nonfatal stroke, or death from cardiovascular causes;
hazard ratio [HR]: 0.88, 95% confidence interval [CI]:
0.7 to 1.06) (6). Further, participants in the intensive
BP treatment arm of the ACCORD BP trial experienced
more serious adverse events related to BP medica-
tions than participants in the standard arm (serious
adverse event rate 3.3% vs. 1.3%; p < 0.0001) (6).
A new possibility to inform clinical decisions in the
presence of conflicting trial results is to quantita-
tively assess the generalizability of a trial to the
population of patients among whom the clinical de-
cision is meant to apply. Recent advances in statisti-
cal approaches called “transportability methods”
allow us to quantify how the results of the ACCORD
BP trial may generalize to the broader U.S. population
of patients with DM, and specifically estimate howmuch the general population might experi-
ence different outcomes from intensive BP
treatment than the result seen in the ACCORD
BP trial (7–11). Transportability methods can
be thought of as reweighting the results from
each member of the trial sample to construct
a pseudopopulation that matches the de-
mographics and clinical characteristics of the
broader national population with DM. By
weighting the trial results, the overall effec-
tiveness of intensive BP treatment for the
more general population can be estimated,
helping to inform whether individual practi-
tioners may be wary or eager to implement
intensive BP treatment among patients with
DM.
Here, we sought to identify how the ACCORD BP 
study results may be generalized to people with DM 
in the United States, and thereby inform recommen-
dations for BP treatment.
METHODS
SOURCE OF DATA AND SAMPLE SIZE. Individual 
patient data from the ACCORD BP trial (n ¼ 4,507) (6), 
and individual-level data pooled from repeated cross 
sections of the NHANES (National Health and Nutri-
tion Examination Survey, 2005 to 2014, n ¼ 1,943), a 
nationally representative population-based epidemi-
ological surveillance study of noninstitutionalized 
Americans (12) were used to conduct the study. Ana-
lyses incorporated NHANES design information, 
including sampling weights and clustering, as 
appropriate. We did not use data from the SPRINT 
trial in this study because the SPRINT trial did not 
include individuals with DM, and thus data on several 
relevant cardiovascular risk factors for individuals 
with diabetes were not measured. Further, the 
SPRINT trial did not release socioeconomic status 
information that would be used for transportability 
estimates (5).
PARTICIPANTS.  ACCORD  BP  t r ia l .  Detailed infor-
mation on the study design and main outcomes of the 
ACCORD BP trial were previously published (6). In
brief, the ACCORD trial enrolled 10,251 type 2 diabetes 
patients with a history of a hemoglobin A1c (HbA1c)
>7.5%, and cardiovascular disease (if age >40 years)
or high cardiovascular risk (if age >55 years) to an
intensive versus standard glycemic control strategy.
Using a 2  2 factorial design, patients were addi-
tionally assigned to either a lipid-lowering study (the
ACCORD lipid trial) or a BP-lowering study (ACCORD
BP, N ¼ 4,733). Additional entry criteria for the
ACCORD BP trial are described in the study protocol,
TABLE 1 Demographic and Clinical Characteristics of NHANES and ACCORD Participants
ACCORD
Before Weighting






(n ¼ 4,507) p Value ASD
Baseline age, yrs 62.76  6.70 <0.001 0.30 59.65  13.70 60.87  6.59 0.002 0.13
Female 47.4 0.42 0.03 48.8 48.4 0.87 0.01
Race/ethnicity <0.001 0.34 <0.001 0.34
Non-Hispanic white 58.9 61.8 45.5
Non-Hispanic black 23.9 15.3 19.6
Hispanic 6.9 15.4 25.5
Asian/multi/other 10.4 7.5 9.4
Education <0.001 0.29 <0.001 0.20
Less than HS 16.2 26.8 31.9
HS diploma 26.8 27.0 19.1
Some college 32.5 29.1 29.1
College diploma or higher 24.5 17.1 19.9
Insured 84.6 0.91 0.07 86.8 84.9 0.18 0.06
Smoking status <0.001 0.18 0.03 0.11
Never 44.9 51.1 56.7
Current 13.1 15.4 13.6
Former 42.0 33.4 29.7
History of CHF 4.3 <0.001 0.19 9.0 11.1 0.26 0.07
History of MI 13.8 0.002 0.10 10.5 11.0 0.68 0.02
History of stroke 6.4 0.02 0.08 8.4 7.9 0.70 0.02
Years with diabetes 10.86  7.84 <0.001 0.38 7.49  9.19 10.53  7.56 <0.001 0.35
BMI, kg/m2 32.16  5.46 0.003 0.11 32.80  7.30 32.62  5.87 0.37 0.04
SBP, mm Hg 139.23  15.83 <0.001 0.51 130.08  19.15 132.93  15.04 <0.001 0.16
DBP, mm Hg 76.01  10.35 <0.001 0.62 69.51  12.96 71.88  10.05 <0.001 0.31
FPG, mg/dl 174.90  57.82 <0.001 0.33 151.87  54.57 180.23  66.36 <0.001 0.39
HbA1c, % 8.34  1.09 <0.001 0.78 7.16  1.64 8.07  1.03 <0.001 0.59
HDL, mg/dl 46.16  13.64 <0.001 0.15 49.11  13.45 50.87  16.36 <0.001 0.17
LDL, mg/dl 109.93  36.75 <0.001 0.16 103.86  36.02 105.44  34.10 0.41 0.04
Triglycerides, mg/dl 193.70  176.29 0.001 0.11 148.89  76.09 127.11  68.86 <0.001 0.35
Estimated GFR, ml/min 91.54  28.93 <0.001 0.15 87.46  28.09 84.12  21.68 0.003 0.12
Urine albumin to creatinine ratio 93.15  326.11 0.63 0.02 75.41  481.22 197.62  739.92 0.004 0.17
Values are mean  SD or %. Means and percentages for NHANES are nationally representative using NHANES sampling weights and clustering variables. p and ASD values are in
comparison to NHANES.
ASD ¼ absolute standardized difference; BMI ¼ body mass index; CHF ¼ congestive heart failure; DBP ¼ diastolic blood pressure; FPG ¼ fasting plasma glucose;
HbA1c ¼ hemoglobin a1c; HDL ¼ high-density lipoprotein cholesterol; HS ¼ high school; GRF ¼ glomerular filtration rate, estimated by the modification of diet in renal disease
equation; LDL ¼ low-density lipoprotein cholesterol; MI ¼ history of myocardial infarction; NHANES ¼ National Health and Nutrition Examination Survey; SBP ¼ systolic blood
pressure.but include having a systolic blood pressure (SBP)
between 130 and 180 mm Hg on 3 or fewer BP-
lowering medications, and urinary protein
excretion <1.0 g in 24 h. Participants in the ACCORD
BP trial were randomly assigned to the intensive BP
treatment (n ¼ 2,362; goal SBP <120 mm Hg; achieved
mean SBP after 1 year 119.3 mm Hg) or standard BP
treatment (n ¼ 2,371; goal SBP <140 mm Hg; achieved
mean SBP after 1 year 133.5 mm Hg) arm. Treatment
was not blinded, and strategy for achievement of that
the treatment goal (e.g., choice of medications and
dose adjustment) was determined by individual study
physicians under broad guidance. The maximum
duration of follow-up was 7 years.
NHANES. To determine the sociodemographic and
clinical characteristics of the civilian U.S. populationof patients with DM, we used demographic, ques-
tionnaire, examination, and fasting laboratory data
from NHANES pooled across 10 years (2005 to 2014),
which incorporates the most recent data available.
As in prior studies, DM was defined as patient self-
report of a diagnosis of diabetes, HbA1c >6.5%, or
fasting plasma glucose (FPG) >126 mg/dl (13–15). We
did not distinguish between type 1 and type 2 dia-
betes in this study because current BP guidelines do
not. Because current guidelines are meant to apply
to adults, we included NHANES participants $20
years of age, and because separate guidelines exist
for management of BP in pregnancy, we excluded
those currently pregnant. Because we were con-
cerned that data within NHANES may not distin-
guish between those with controlled hypertension
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NHANES ACCORD: Observed ACCORD: Re-weighted
Berkowitz, S.A. et al. J Am Coll Cardiol. 2018;72(11):1214–23.
The Kaplan-Meier estimates of experiencing the ACCORD BP primary outcome (a composite of first occurrence of nonfatal myocardial infarction, nonfatal stroke, or
cardiovascular death), in the unweighted (left) and weighted (right) analyses. ACCORD ¼ Action to Control Cardiovascular Risk in Diabetes trial; BP ¼ blood pressure.from those without hypertension, we did not have
explicit hypertension-related inclusion criteria in
our main analyses. However, to investigate whether
this decision could affect the results, we performed
2 sensitivity analyses. In the first, in addition to the
aforementioned criteria, we also required a self-
report of hypertension diagnosis, a self-report oftaking a BP-lowering medication, a SBP measure-
ment (averaged over all NHANES measurements) of
>130 mm Hg, or a diastolic BP measurement (aver-
aged over all NHANES measurements) of
>80 mm Hg (2). The second sensitivity analysis
sample required that SBP (averaged over all
NHANES measurements) be between 130 and
TABLE 2 Relative Risk of Outcomes for Intensive Versus
Standard BP Therapy
Unweighted Weighted
HR/IRR 95% CI HR/IRR 95% CI
Primary outcome 0.88 0.73–1.07 0.67 0.49–0.91
Total mortality 1.07 0.85–1.35 0.91 0.62–1.32
Stroke 0.59 0.39–0.89 0.33 0.17–0.62
Microvascular outcome 1.07 0.90–1.27 1.00 0.75–1.33
Serious adverse events 1.93 1.37–2.72 1.97 1.09–3.58
All estimates represent hazard ratios (HRs) and 95% confidence intervals (CIs)
from proportional hazards regression models except for serious adverse events
which represents incidence rate ratios from negative binomial models. Models are
adjusted for intensive versus standard glycemic therapy, clinical network, and
history of cardiovascular disease at baseline.
BP ¼ blood pressure; IRR ¼ incidence rate ratio.180 mm Hg, which closely matches an ACCORD BP
eligibility criterion (6).
OUTCOMES. The outcomes for this study matched
those of the ACCORD BP trial. The primary outcome
was a composite of first occurrence of nonfatal MI,
nonfatal stroke, or cardiovascular death. Secondary
outcomes used in this study were all-cause mortality,
total (fatal and nonfatal) stroke, the main microvas-
cular composite outcome from the ACCORD trial (first
occurrence of renal failure [initiation of dialysis or
end-stage renal disease, renal transplantation, or rise
of serum creatinine >291.72 mmol/l] or retinal photo-
coagulation or vitrectomy to treat retinopathy), and
number of serious nonhypoglycemic adverse events
(defined as hypotension, syncope, bradycardia or
arrhythmia, hyperkalemia, or renal failure, attribut-
able to the study medication) (6).
FACTORS USED FOR WEIGHTING. We considered
several potential effect modifiers that may alter the
risk or benefit of intensive versus standard BP
treatment. These factors were selected on the basis
of prior evidence or hypotheses for their association
with cardiovascular disease risk (3,16–20). The fac-
tors considered were age, sex, race/ethnicity (cate-
gorized as non-Hispanic white, non-Hispanic black,
Hispanic, and other/multiracial), education (catego-
rized as less than high school diploma, high school
diploma, some college, or college degree and
higher), health insurance status (insured/uninsured),
tobacco smoking status (never, current, former),
history of MI, history of congestive heart failure,
history of stroke, SBP, diastolic BP, total cholesterol,
high-density lipoprotein cholesterol, low-density li-
poprotein cholesterol, triglycerides, HbA1c, FPG,
glomerular filtration rate (estimated using the 4-
term modification of diet in renal disease equa-
tion), urinary albumin to creatinine ratio, and body
mass index (Table 1). All potential effect modifier
measurements from the ACCORD BP study were
taken from baseline (pre-treatment) examinations.
Data from the ACCORD BP trial and NHANES were
inspected for implausible values, but only a small
number of diastolic BP readings <30 mm Hg from
NHANES were identified and excluded from the
analysis.
MISSING DATA. Missing data were not imputed
because missingness was <5% for any variable.
STATISTICAL ANALYSIS. To generalize the ACCORD
BP results to the NHANES population (i.e., to “trans-
port” the results from the ACCORD BP trial to
NHANES), we used a stabilized inverse odds of
selection weighting approach that is analogous to
propensity score weighting (8). The intuition behindthis approach is to up-weight individuals in the
ACCORD BP trial who have characteristics that are
more common in NHANES, and down-weight those in
the ACCORD BP trial with characteristics less common
in NHANES (Central Illustration). To calculate the
weights, the probability of not being included in the
ACCORD trial was calculated for each person in
NHANES, conditional on the aforementioned cova-
riates, divided by their individual probability of being
in the ACCORD trial, conditional on the aforemen-
tioned covariates. The odds were then multiplied by a
stabilization factor, which was the unconditional
probability of being included in the ACCORD trial
divided by the unconditional probability of not being
included. In mathematical terms, the stabilized
inverse odds of selection were:
ð1 pjZÞ=ðpjZÞ$ðp=1 pÞ
where p is the probability of selection and Z is the
vector of individual covariates. To estimate the con-
ditional probability of selection, we fit a logistic
regression model (Online Table 1) with the outcome of
being in the ACCORD trial and the above covariates;
NHANES sampling weights were then multiplied by
the calculated selection weights to generate a
nationally-representative population. The uncondi-
tional probability of selection was based on a null
(intercept-only) logistic regression model, again
incorporating NHANES weights. As a robustness
check, we re-estimated the probabilities using a ma-
chine learning approach that can capture nonlinearity
between covariates and the outcome and complex
interactions among covariates in a more sophisticated
manner than standard logistic regression (Online
Table 2) (21). Weights were Winsorized at the 2.5















Person-Years Difference p Value
Events
per 1,000
Person-Years Difference p Value
Primary outcome
Standard 21.27 2.29 0.24 20.18 5.77 0.03
Intensive 18.98 14.40
Total mortality
Standard 12.15 0.83 0.50 11.82 0.80 0.72
Intensive 12.99 11.02
Stroke
Standard 5.41 2.20 0.01 5.42 3.68 0.002
Intensive 3.21 1.74
Microvascular
Standard 24.50 2.00 0.41 26.80 0.01 0.98
Intensive 26.50 26.79
Serious adverse events
Standard 4.47 4.18 0.0003 3.41 3.64 0.01
Intensive 8.66 7.04
p values from log-rank test, except for serious adverse events, which used Wilcoxon. Weighted analyses used
design-corrected versions.
BP ¼ blood pressure.Outcome metr i cs . We calculated outcome metrics
on both relative and absolute scales. For results on a
relative scale, we used the same analytic approach as
the main the ACCORD BP trial analysis, fitting pro-
portional hazard (Cox) regression models that contain
terms for intensive versus standard BP treatment,
adjusting for intensive versus standard glycemic
treatment arm, clinical center, and previous history
of cardiovascular event (6). A previous study revealed
that the proportional hazards assumption was
reasonable in the ACCORD BP trial (6). We present
unweighted results, which replicate the results of the
main ACCORD BP paper as a check on our analysis,
and results weighted by the inverse odds of selection
to produce estimates transported to the NHANES
population. Because the version of the ACCORD trial
data available to us provides counts of serious
adverse events rather than exact time-to-event data
(to protect confidentiality), we used unweighted and
weighted negative binomial models, offset by the
person-time of follow-up for all-cause mortality, to
model serious adverse events. Robust standard errors
with independent covariance structure were esti-
mated to calculate 95% CIs.
For results on the absolute scale, we calculated
number of events per 1,000 person-years of follow-
up, and plotted the survival function for time-to-
event outcomes using Kaplan-Meier methods. We
applied log-rank tests for significance of time-to-
event outcomes, and the Wilcoxon 2-sample test
(Mann-Whitney U test) for serious adverse events
with a design correction factor for weighted analyses.
Sens i t i v i ty and robustness checks . First, we con-
ducted Cox/negative binomial regression analyses
adjusting for factors that had an absolute standard-
ized difference >0.2 after weighting, to correct for
residual imbalance between the weighted ACCORD
BP trial population and the NHANES population.
Second, we repeated analyses using a targeted
maximum likelihood estimation approach, which has
been shown to be less sensitive to positivity viola-
tions (cases where some combinations of important
covariates are not observed in both the ACCORD BP
and NHANES datasets) (9,10). Next, we fit nested
conditional probability models to identify combina-
tions of characteristics that might be responsible for
differences in transported and untransported treat-
ment effects. These models sequentially added sub-
sets of the full set of cardiovascular risk factors based
on imbalance between the ACCORD BP sample and
the overall population. Finally, we fit the same
weighted proportional hazards models in samples
that additionally required hypertension-related in-
clusion criteria, as described above, to be met.All analyses followed the intention-to-treat prin
ciple for treatment group assignment. A 2-sided p
value <0.05 was taken to indicate statistical signifi
cance. Analyses were conducted in SAS 9.4 (SAS
Institute, Cary, North Carolina) (PROC LOGISTIC and
PROC PHREG) and R 3.4.2 (R Foundation for Statisti
cal Computing, Vienna, Austria). Statistical code fo
replication is available from the authors.
The human research committee at Partners
Healthcare approved this study of secondary data.
RESULTS
STUDY PARTICIPANT CHARACTERISTICS. Overall
4,507 participants from the ACCORD BP study were
included, consisting of 2,261 in the intensive treat
ment arm and 2,246 in the standard arm. The median
follow-up time for the primary outcome was 4.92
years. There were 1,943 adults with diabetes included
from the NHANES dataset. Comparisons between
ACCORD BP and NHANES participants revealed sig
nificant differences between the study groups. In
particular, ACCORD BP participants had less racial
ethnic diversity, greater education, and more
elevated cardiovascular risk factors than the overal
population (Table 1).
TRANSPORTED RESULTS FROM ACCORD BP TO
NHANES. After weighting the ACCORD BP population
to NHANES, the weighted ACCORD BP sample was
more representative of the overall population, but as
would be expected by the study design, some










Hazard Ratio for Primary Outcome
Favors Intensive Therapy Favors Standard Therapy
1.0 1.25 1.5
Demographic characteristics weighting includes age, sex, race/ethnicity, education, and health insurance status. Clinical risk factors weighting
includes smoking status, history of myocardial infarction, history of congestive heart failure, history of stroke, systolic blood pressure,
diastolic blood pressure, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, hemoglobin A1c, fasting
plasma glucose, glomerular filtration rate, urinary albumin to creatinine ratio, and body mass index. Two models specifically explore the
influence of factors that were particularly unbalanced when weighting for all factors. By weighting only for these subsets of factors, we can
achieve better balance on them then when weighting for the totality of the factors. For these analyses, subset 1 includes race/ethnicity,
education, systolic blood pressure, triglycerides, high-density lipoprotein cholesterol, and urine albumin to creatinine ratio. Subset 2 adds
years of diabetes duration to subset 1. Fully weighted includes all demographic characteristics and clinical risk factors.imbalances remained, particularly in terms of racial/
ethnic diversity, HbA1c, FPG, and duration of diabetes
(Table 1). In general, weighting increased the pro-
portion of individuals who were Hispanic, and those
who had lower HbA1c, fasting glucose, and shorter
duration of diabetes along with other changes as
indicated in Table 1. The weights ranged from 0.01 to
4.67 (Online Figure 1).
In analyses examining the primary outcome,
weighted results favored intensive BP treatment,
unlike the unweighted results (HR for the primary
outcome in intensive versus standard treatment in
weighted analyses 0.67; 95% CI: 0.49 to 0.91)
(Table 2). In absolute terms, the transported results
would indicate 14.4 cardiovascular events in the
intensive BP treatment arm versus 20.2 in the stan-
dard arm per 1,000 person-years (p ¼ 0.03), with a
number needed to treat of 172 over 1 year and 34 over
5 years to avert 1 cardiovascular event (Table 3). These
contrast with the unweighted results of 21.27 events
per 1,000 person-years in the standard arm and 18.98
in the intensive arm (p ¼ 0.24).
In the weighted analyses, total mortality (HR: 0.91;
95% CI: 0.62 to 1.32) was not different between
intensive and standard therapy groups, nor was the
risk of microvascular events (HR: 1.00; 95% CI: 0.75 to
1.33). Stroke outcomes favored intensive therapy (HR:0.33; 95% CI: 0.17 to 0.62), showing more favorable
point estimates in weighted versus unweighted ana-
lyses (unweighted HR: 0.59; 95% CI: 0.39 to 0.89).
Weighted and unweighted Kaplan-Meier plots
showing absolute outcome metrics for the time-to-
event outcomes are presented in Online Figures 2 to 9
and were consistent with the relative outcome met-
rics. Serious adverse events were more common in
the weighted intensive therapy group (incidence rate
ratio 1.97; 95% CI: 1.09 to 3.58, number needed to
harm of 275 at 1 year or 55 at 5 years), and the esti-
mate was similar to that of the unweighted analyses
(unweighted incidence rate ratio 1.93; 95% CI: 1.37 to
2.72).
In sensitivity analyses that adjusted for residually
imbalanced factors (race/ethnicity, education, dia-
stolic BP, FPG, HbA1c, triglycerides, and years with
diabetes), point estimates were more strongly in favor
of intensive BP therapy than in the weighted but un-
adjusted analyses (Online Table 3), though adjust-
ment did not produce any qualitative changes. In
sensitivity analyses additionally requiring hyperten-
sion diagnosis or elevated BP as inclusion criteria,
estimates were similar to the main analyses (Online
Tables 4 and 5). In sensitivity analyses using tar-
geted maximum likelihood estimation, estimates
were again more strongly in favor of intensive BP
therapy (Online Table 6). In analyses using nested
models, weighting for demographic factors or clinical
risk factors only did not fully explain the differences
between unweighted and weighted results, but the
combination of demographic and clinical factors
(particularly race/ethnicity, education, SBP, tri-
glycerides, high-density lipoprotein cholesterol, urine
albumin to creatinine ratio, and years of diabetes
duration) yielded results most similar to the “fully”
weighted results (Figure 1, Online Tables 7 and 8).
DISCUSSION
We sought to transport the results of the ACCORD BP
trial to a population more representative of Ameri-
cans with diabetes, and found that intensive BP
therapy would be expected to be associated with
lower risk for the primary outcome of nonfatal MI,
nonfatal stroke, or cardiovascular death, along with
lower risk for stroke alone, in the general DM popu-
lation. The estimated benefit of intensive treatment
seen after reweighting is in line with those observed
in the SPRINT trial, which helps harmonize the results
of the 2 studies (5). These findings favor intensive BP
treatment, but also highlight the lack of data support
for BP treatment guidance in large segments of the
U.S. adult population with DM—particularly racial/
ethnic minorities and those with lower cardiovascular
risk.
The magnitude of the estimated reduction in the
primary outcome suggested a number needed to treat
of 172 at 1 year and 34 at 5 years to avert one cardio-
vascular event. For reference, the ACC/AHA guide-
lines recommend treatment in those with a 10-year
risk >10%, which will have a number needed to treat
of around 300 at 1 year (2,24). Intensive therapy was
also associated with reduced stroke incidence in
weighted estimates, similar to unweighted estimates,
but no difference in all-cause mortality or microvas-
cular complications of diabetes. Intensive therapy
was associated with a number needed to harm of 275
at 1 year.
These findings offer significant new contributions
to the published reports on BP guidelines, and to the
published reports on the interpretation of clinical trial
results more broadly. Current guidelines for BP treat-
ment among patients with diabetes do not restrict
their recommendations to those included in major
trials, and vary notably in their target BP recommen-
dations (2). Guideline committees and individual
practitioners do not have the luxury of waiting for a
randomized controlled trial that perfectly matches the
general U.S. population or a particular patient panel
before making treatment recommendations ordecisions; because randomized controlled trials are
expensive and time consuming, and it is sometimes
difficult to enroll certain groups, attempting to
generalize trial results among a selected participant
population to a more real-world population is inevi-
table. This is not a criticism; in the absence of a
directly applicable trial, the alternative to trans-
porting results is not to use trial results at all. How-
ever, recent statistical advances have allowed us to
transport results quantitatively and formally (7–9),
rather than in an informal or qualitative way, which
may help advise clinical practice guidelines and help
inform practitioners faced with diverging guidelines.
Our work also informs the specific interpretation of
the SPRINT and ACCORD BP trials. Prior work
analyzing who benefits most from intensive BP
treatment found that non-Hispanic black race/
ethnicity was associated with greater benefit (25).
Another reanalysis of ACCORD BP data found that,
among a subset of ACCORD BP participants who
would have been eligible for SPRINT (apart from DM),
intensive BP treatment reduced a composite outcome
of cardiovascular events (26). Finally, prior work
found that the relative benefit of treatment may be
greater in those with lower, compared with higher,
cardiovascular risk (27). These results are all consis-
tent with the current study, where we observed more
relative benefits of intensive BP treatment when the
overall risk was lower. Conversely, this finding does
differ from a meta-analysis of BP trials that did not
find different relative risks associated with BP treat-
ment as cardiovascular risk varied (24). However, that
meta-analysis did not include ACCORD BP or SPRINT
data. Further, subgroup analyses of the ACCORD
BP trial in the original paper (6) suggested larger
benefits with intensive therapy in individuals with
lower baseline HbA1c and lower diastolic BP (though
interaction terms were not significant). Because the
U.S. population with diabetes has lower HbA1c and
BP than the included sample, reweighting the
study likely emphasized the experience of those
participants.
STUDY LIMITATIONS. Transport methods can only
standardize results over variables that have been
measured. If data on important risk factors, such as
social factors that may modify the effectiveness of
therapy in the real world, are not available, and differ
between the original and transported population,
then the results may not fully reflect what would
happen if the intervention was applied to the new
population. Design choices about who to include in
the ACCORD sample also make it more difficult to
apply results to the overall U.S. population, as indi-
cated by residual lack of balance for some factors.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: High
blood pressure is a major modifiable risk factor for
cardiovascular events in patients with diabetes.
TRANSLATIONAL OUTLOOK: Randomized trials
should include more diverse cohorts and patients at
lower cardiovascular risk to better reflect the target
population and enhance clinical practice guidelines.Because the ACCORD BP trial specifically recruited
individuals at high cardiovascular risk (higher than
average for an individual with diabetes), there is poor
overlap between the ACCORD BP trial and the U.S.
population for some low risk groups. This leads to
uncertainty in estimating the potential effects of
intensive BP control, and should prompt caution in
interpreting the study results until they can be
confirmed in samples that better match the overall
U.S. population of adults with DM. Further, the pub-
licly available data on serious adverse events does not
make it possible to attribute specific adverse events
to BP (as opposed to glycemia) medications, or to
conduct time-to-event analyses for this outcome.
The results of this study, in light of the new
ACC/AHA guidelines (2), bring up the unanswered
question of what to do when transported results
qualitatively differ from those of the original trial.
Given the novelty of transportability methods,
we believe it is best to view the results of this study
as hypothesis generating until more rigorous pro-
spective validation of transportability methods,
such as post-transportability clinical studies, enable
us to formally assess outcomes among patients
treated with and without clinical decisions informed
by transportability analyses. Next, the residual
imbalance between the weighted ACCORD BP and
NHANES populations does highlight areas where the
evidence favoring intensive BP has less data support.
To address this, we conducted sensitivity analyses
adjusted for residual imbalance between the
weighted ACCORD BP and NHANES populations, and
we used methods that were less sensitive to the un-
representativeness of the ACCORD BP trial. In both
cases, results were even more in favor of intensive BP
therapy than our base case analysis; this suggests that
residual confounding and lack of representativeness
of the ACCORD BP trial are unlikely to explain our
observed results. However, future studies should
examine further the robustness of the intensive BP
effect among racial/ethnic minorities with lower
baseline cardiovascular risk, who were the least-
informed by the ACCORD BP results. This brings up
an important gap in knowledge for future research:how much to transport results when data that directly
answer the question have limited availability and
require higher weighting of few individuals. Our re-
sults also suggest several more directions for future
research. Analyses only weighting for demographics
or cardiovascular risk alone had smaller changes than
those accounting for both demographics and clinical
risk factors, which suggests there may be some
interaction between demographic and cardiovascular
risk factors worth exploring when analyzing hetero-
geneous treatment effects, rather than relying only
on univariate subgroup analyses (28).
CONCLUSIONS
Overall, our study helps to make quantitative judg-
ments regarding how to generalize trial results to a
broader population. Additionally, the methods high-
light the specific areas where existing evidence pro-
vides the most or least support. Although lack of data
in some groups means results supporting intensive
BP treatment should be interpreted cautiously, it also
highlights areas that need further study to better
inform BP treatment guidelines.
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